Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

First Posted Date
2008-08-14
Last Posted Date
2016-05-30
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
18
Registration Number
NCT00734344
Locations
🇺🇸

UAB 1917 Clinic, Birmingham, Alabama, United States

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

First Posted Date
2008-06-16
Last Posted Date
2013-06-06
Lead Sponsor
Fran Aweeka
Target Recruit Count
38
Registration Number
NCT00697892
Locations
🇺🇸

San Francisco General Hospital, San Francisco, California, United States

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

Not Applicable
Completed
Conditions
HIV
Interventions
Drug: Efavirenz
First Posted Date
2008-04-29
Last Posted Date
2014-09-26
Lead Sponsor
Indiana University
Target Recruit Count
73
Registration Number
NCT00668395
Locations
🇺🇸

Indiana Clinical Research Center (ICRC), Indianapolis, Indiana, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Not Applicable
Completed
Conditions
HIV Infections
AIDS
Interventions
Drug: raltegravir
Drug: efavirenz
First Posted Date
2008-04-21
Last Posted Date
2017-05-30
Lead Sponsor
University of California, Davis
Target Recruit Count
25
Registration Number
NCT00661960
Locations
🇺🇸

CARES Clinic, Sacramento, California, United States

🇺🇸

UC Davis Medical Center, Sacramento, California, United States

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Kivexa plus Sustiva
Drug: Atripla
First Posted Date
2008-02-14
Last Posted Date
2010-08-02
Lead Sponsor
Gilead Sciences
Target Recruit Count
159
Registration Number
NCT00615810
Locations
🇬🇧

Gilead Sciences, Granta Park, Cambridge, Abington, United Kingdom

Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage

Phase 4
Completed
Conditions
HIV-1 Infection
HIV Infection
Interventions
Drug: Efavirenz
First Posted Date
2007-11-12
Last Posted Date
2009-01-15
Lead Sponsor
Sociedad Andaluza de Enfermedades Infecciosas
Target Recruit Count
114
Registration Number
NCT00556634
Locations
🇪🇸

Hospital Juan Ramon Jimenez, Huelva, Spain

🇪🇸

Hospital Universitario Puerta del Mar, Cadiz, Spain

🇪🇸

Hospital Torrecardenas, Almeria, Spain

and more 7 locations

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

First Posted Date
2007-10-17
Last Posted Date
2014-08-12
Lead Sponsor
University of Cincinnati
Target Recruit Count
18
Registration Number
NCT00545558
Locations
🇺🇸

General Clinical Research Center (GCRC), OH site, Cincinnati, Ohio, United States

🇺🇸

Virginia Commonwealth University, School of Medicine, Richmond, Virginia, United States

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Phase 3
Completed
Conditions
HIV Infections
HIV-1
Interventions
Drug: TMC278
Drug: efavirenz
First Posted Date
2007-10-15
Last Posted Date
2016-04-01
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
680
Registration Number
NCT00543725

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

First Posted Date
2007-10-08
Last Posted Date
2016-03-29
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
694
Registration Number
NCT00540449

Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

Phase 4
Terminated
Conditions
Tuberculosis
HIV Infections
Interventions
Drug: efavirenz
First Posted Date
2007-09-21
Last Posted Date
2015-11-10
Lead Sponsor
Oswaldo Cruz Foundation
Target Recruit Count
130
Registration Number
NCT00533390
Locations
🇧🇷

FIOCRUZ Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

🇧🇷

Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy